Overview
- 45 inspections across 43 sites are on record.
- 13 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-04-17.
At a glance
Inspections
45
Sites
43
Observations
13
Career since
Jan 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. | 17 Apr 2026 | Human Drugs | |
| Sichuan Huiyu Pharmaceutical Co., Ltd. | 16 Apr 2026 | Human Drugs | |
| Regeneron Pharmaceuticals Inc | 10 Dec 2025 | Human Drugs | |
| NORTHEAST BIOLAB | 5 Dec 2025 | Human Drugs | On file |
| Cohance Lifesciences (fka RA Chem Pharma Ltd.) | 31 Oct 2025 | Human Drugs | On file |
Sites inspected
Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd.Chengdu, China1 insp.
Sichuan Huiyu Pharmaceutical Co., Ltd.Nei Jiang, China1 insp.
Regeneron Pharmaceuticals IncTarrytown, United States1 insp.
NORTHEAST BIOLABHamden, United States1 insp.
Cohance Lifesciences (fka RA Chem Pharma Ltd.)Hyderabad, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Xikui Chen4 shared
Sripal R Mada4 shared
Makini Cobourne-Duval4 shared
Amanda Lewin3 shared
Li-Hong Yeh3 shared
Nicola M Fenty-Stewart3 shared
Courtney N Long2 shared
Sarmistha Sanyal2 shared
Gopa Biswas2 shared
Gajendiran Mahadevan2 shared
Full investigator report
Get the verbatim findings behind Melkamu Getie Kebtie's 13 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site